Veliter Mole-Scale GMP Oligonucleotide Production Facility Breaks Ground in Changsha Injecting Vital Momentum into the Development of Innovative Medicine

A Grand Beginning, Shaping a Glorious Future Together

On December 2, 2024, the groundbreaking ceremony for the “Veliter Mole-Scale GMP Production Facility Construction Project” took place at the Tongguan Industrial Zone of Wangcheng Economic and Technological Development District, Changsha. The project is built by Hunan Veliter Biomedicine Co., Ltd., an affiliated company funded by the same shareholders as Guangdong Veliter Biomedical Technology Co., Ltd. (hereinafter referred to as “Veliter”). Upon completion, the facility will expand production capacity of oligonucleotide drugs from the current 25 kilograms per year to 120-150 kilograms per year. This marks a significant milestone forward in Veliter’s global strategy and production line upgrade, vigorously driving Chinese even global industrial capabilities in treating critical diseases and infusing vitality into the development of innovative nucleic acid therapeutics.

The groundbreaking ceremony was attended:Economic and Technological Development Zone, Veliter Founder & CEO Mr. Alex Xu, shareholders Mr. Youliang Xu, Mr. Xiaobin Liang, and Mr. Yecheng Liang, along with other senior executives.

Gathering of Distinguished Guests to Celebrate the Milestone

The event was graced by partners, key clients, and investment institutions from far and wide, adding luster to the occasion and witnessing this historic moment. During the ceremony, Mr. Alex Xu, Veliter’s Founder & CEO, delivered an inspiring speech, warmly welcoming the attendees and expressing heartfelt gratitude to partners for their long-standing support. He emphasized that the initiation of the mole-scale GMP project would set up a new standard in the oligonucleotide industry, contributing to the creation of a highly efficient, environmentally friendly, and comprehensive nucleic acid platform. Mr. Linbo Kuang from The 23rd Metallurgical construction group col, ltd. of Minmetals also gave a speech, affirming the company’s commitment to ensuring the high-quality and timely completion of the project. Additionally, Mr. Damien Wei, General Manager of Global Life Sciences Technologies (Shanghai) Co., Ltd. announced a commitment to provide full support and services for the successful execution and operation of the project.

Foundation Laying: A New Chapter Begins

As officially announced the start of the foundation-laying ceremony, leaders and guests wielded golden shovels to place soil onto the foundation stone. This moment not only symbolized collective effort and anticipation but also heralded a promising future for the project.

Looking Ahead: Joining Hands for the Future

Veliter Mole-Scale GMP Production Facility Project leverages advanced technology and a professional team to establish a service hub for global nucleic acid pharmaceutical innovators, with Hunan and Guangdong as its core. It aims to provide authoritative, efficient, and comprehensive oligonucleotide CDMO (Contract Development and Manufacturing Organization) services to research institutes, bio-technical and bio-pharmaceutical companies. Veliter is committed to continously upgrading its R&D capabilities, process development, and production capacity, thereby building a reliable and efficient oligonucleotide service platform with one-stop oligonucleotide CDMO solutions and contributing to technological advancements and quality enhancement in the nucleic acid industry.

“Veliter Embarks on a New Journey; Nucleic Acid Pharmaceuticals Shape the Future” — Dedicated to becoming the preferred partner for gene therapy innovators and fulfilling the noble mission of improving the lives of patients worldwide. On this land, Veliter will rise with ambition and responsibility, creating a modern ‘health fortress’ to power the growth of innovative medicine development!”